levodopa methyl ester has been researched along with Idiopathic Parkinson Disease in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 8 (47.06) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Auger, F; Barthelemy, C; Bezard, E; Bordet, R; Carta, N; Defebvre, L; Demailly, A; Deramecourt, V; Devedjian, JC; Devos, D; Duce, J; Fisichella, M; Kuchcinski, G; Laloux, C; Lannoy, D; Li, Q; Moreau, C; Odou, P; Pioli, E; Rolland, AS | 1 |
| Campisi, G; De Caro, V; Giannola, LI; Scaturro, AL | 1 |
| Cacciatore, I; Conte, C; Cornacchia, C; Minelli, A; Pinnen, F; Prudenzi, E; Taha, E | 1 |
| Dall'Armi, V; Kulisevsky, J; Lamberti, P; Obeso, JA; Stocchi, F; Zappia, M | 1 |
| Bosco, D; Bosco, F; Fava, A; Plastino, M; Rotondo, A | 1 |
| Cooper, DR; Jenner, P; Marrel, C; Marsden, CD; Quinn, N; Testa, B; van de Waterbeemd, H | 1 |
| MartÃ, MJ; Tolosa, ES; Valldeoriola, F | 1 |
| Barbato, L; Marsden, CD; O'Connel, MT; Patsalos, PN; Quinn, NP; Ruggieri, S; Stocchi, F | 1 |
| Barbato, L; Bramante, L; Nordera, G; Ruggieri, S; Stocchi, F; Vacca, L | 1 |
| Bonastre, M; Chase, TN; Engber, TM; Marin, C; Papa, S; Tolosa, E | 1 |
| Bramante, L; Quinn, NP; Ruggieri, S; Steiger, MJ; Stocchi, F | 1 |
| Agnoli, A; Carta, A; Jenner, P; Marsden, CD; Quinn, N; Ruggieri, S; Ryatt, J; Stocchi, F | 1 |
| Kleedorfer, B; Lees, AJ; Stern, GM | 1 |
| Agnoli, A; Carta, A; Marsden, CD; Quinn, NP; Ruggieri, S; Steiger, MJ; Stocchi, F | 1 |
| Agnoli, A; Carta, A; Catarci, M; Ruggieri, S; Stocchi, F | 1 |
| Agnoli, A; Antonini, A; Bragoni, M; Carta, A; Ruggieri, SA; Stocchi, F | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM; Serrati, C | 1 |
1 review(s) available for levodopa methyl ester and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
New and emerging strategies for improving levodopa treatment.
Topics: Animals; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 1994 |
5 trial(s) available for levodopa methyl ester and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Intention to Treat Analysis; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2010 |
Daily motor performance after switching levodopa to melevodopa: an open-label on advanced Parkinson's disease with "delayed-on" and/or"wearing-off".
Topics: Antiparkinson Agents; Drug Substitution; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Quality of Life | 2011 |
Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study.
Topics: Aged; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester.
Topics: Administration, Oral; Aged; Analysis of Variance; Antiparkinson Agents; Circadian Rhythm; Delayed-Action Preparations; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects | 1996 |
Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1992 |
11 other study(ies) available for levodopa methyl ester and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Infusions, Intraventricular; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Pilot Projects | 2020 |
Potential transbuccal delivery of l-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue.
Topics: Antiparkinson Agents; Drug Delivery Systems; Drug Stability; Levodopa; Mouth; Mouth Mucosa; Parkinson Disease; Prodrugs | 2016 |
N-acetyl-L-methionyl-L-Dopa-methyl ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity.
Topics: Animals; Animals, Newborn; Antiparkinson Agents; Apoptosis; Cells, Cultured; Cytoprotection; Female; Glutathione; Heme Oxygenase-1; Levodopa; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Neurons; Oxidative Stress; Parkinson Disease; Pregnancy | 2010 |
L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Levodopa; Limbic System; Male; Mice; Parkinson Disease; Reserpine | 1984 |
MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Dizocilpine Maleate; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Prosencephalon; Rats; Rats, Sprague-Dawley; Rotation | 1996 |
The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.
Topics: Benserazide; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1992 |
Subcutaneous and sublingual levodopa methyl ester in Parkinson's disease.
Topics: Administration, Sublingual; Antiparkinson Agents; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1991 |
The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease.
Topics: Administration, Oral; Aged; Benserazide; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1991 |
Jejunal delivery of levodopa methyl ester.
Topics: Humans; Jejunostomy; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1989 |
Continuous dopaminergic stimulation in the management of complicated Parkinson's disease.
Topics: Adult; Ergolines; Female; Humans; Infusions, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1988 |
Levodopa methyl ester treatment of Parkinson's disease.
Topics: Administration, Oral; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |